MSD Animal Health has launched Nobivac(r) Respira Bb, a new injectable vaccine against Bordetella bronchiseptica.

The new vaccine offers 12 months protection when used as a single-dose booster in dogs previously vaccinated with Nobivac(r) KC. It is presented in a 10ml multi-dose vial which can be stored in or out of a refrigerator for 28 days after broaching.

Dogs not previously vaccinated against Bordetella bronchiseptica need two doses administered four weeks apart.

The duration of immunity is 7 months after the primary course and 12 months after a booster with Nobivac(r) Respira Bb. It can also be given 12 months after a primary course in cases where the 7 month dose is missed.

Blaise Scott-Morris, Product Manager, MSD Animal Health said: "Currently only an estimated 1 in 3 vaccinated dogs in the UK are also covered against Bordetella1 so Nobivac(r) Respira Bb offers the chance for practices to re-start the conversation about protection with clients.

"A common barrier to Canine Infectious Respiratory Disease (CIRD) protection, caused by Bordetella, is the belief that it is only necessary for dogs going into kennels, rather than all social dogs. Most dogs meet others however, while out walking, during training, or while attending the vets, and CIRD is infectious even at low levels. Indeed, dogs can be asymptomatic but infectious.

"So, improving protection levels against this disease which is distressing for both the owner and dog, is important in both reducing the risk of outbreaks and the need for antibiotic treatment."

According to the company, trials showed that dogs vaccinated with Nobivac(r) Respira Bb demonstrated a significant reduction in clinical signs of respiratory disease and a reduction in bacterial shedding2. It has also been safely demonstrated in a wide range of breeds3 and has proven efficacy in puppies challenged two weeks after the primary course of vaccination4. It can be given concurrently with many other Nobivac(r) vaccines.

MSD says the new vaccine is most suitable for dogs:

  • When the administration of an intranasal vaccine may be difficult
  • In situations where a risk assessment suggests a live Bordetella vaccine to be less appropriate
  • Which have received recent antimicrobial treatment
  • Which are brachycephalic breeds or have a history of cardiorespiratory disease

Further information can be found at www.nobivacrespiraBb.co.uk, or contact your MSD Animal Health account manager.

References:

  1. Nobivac L4, Nobivac Lepto 2 & Nobivac KC, number of doses, Kynetec VetTrak Data (calendar year November 2020)
  2. MSD Internal Study Reports 0031/16 and S14351
  3. MSD Internal Study Report S15007
  4. MSD Internal Study Report 0031/16

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.